

# ECT Resolving Catatonia in a Huntington's Disease Patient: A Case Report and Review of Literature

Nona A. Nichols, MD<sup>1</sup>; Margaret A. Cinderella, MD<sup>2</sup>; and Sahil Munjal, MD<sup>3</sup>

<sup>1</sup>University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>2</sup>University of North Carolina Health, Chapel Hill, NC; <sup>3</sup>Atrium Health Wake Forest Baptist, Winston-Salem, NC


## Background

Psychiatric symptoms, particularly depression, are common in Huntington's Disease (HD) patients. Catatonia is relatively rare in this population, and there is no current standardized treatment for catatonic HD patients.<sup>1</sup> ECT is not generally used for treatment of psychiatric disorders in HD patients; however, there is evidence that it should be considered for some catatonic HD patients.<sup>2</sup> Here, we present the case of a HD patient with catatonia rapidly responsive to ECT and conduct a literature review, adding further evidence of its efficacy in this population.

## Case

- Mr. S, a 60yoM with a history of HD, depression, and anxiety, presents with suicidal ideation and a plan to overdose due to HD progression and significant anxiety/paranoia about COVID-19.
- Notably, his father died in his early 60s; brother died in his 50s from HD.
- Prior to presentation, discharged from another psychiatric facility following 1 week stay without clinical benefit.
- Admitted with restart of the following psychoactive medications; buspirone 5mg TID, deutetrabenazine 6 mg BID, tiagabine 16 mg QHS, citalopram 40mg daily, paliperidone 3 mg QHS, and propranolol 20mg BID.
- 4 days following presentation, found to have catatonia symptoms. Medication adjustments and treatment course in **Figure 1**.
- **Mr. S recovered from both catatonia and suicidal ideation within 4 treatments of ECT**; he completed 9 inpatient treatments with subsequent tapering to monthly ECT.

Figure 1. Hospitalization Course



BFCRS = Bush-Francis Catatonia Rating Scale

## Case, Continued

- Psychoactive medications at discharge: lorazepam 1 mg TID, propranolol 20mg BID, tiagabine 16mg QHS, and mirtazapine 30mg QHS.
- Patient received a total of 15 ECTs; given improvement in symptoms, all medications aside from lorazepam, propranolol, and trazodone have been discontinued.
- Over 5 months after last ECT, he continues to do well psychiatrically though he has deteriorated physically and resides in a SNF.

## Discussion

- Adequate treatment of depression and psychiatric symptoms in HD patients is paramount given **suicide rate 5x that of general population**.<sup>3</sup>
- Prior literature indicates variable number of ECTs needed to treat catatonia (from 5 to 42 cumulatively),<sup>2</sup> with many patient experiencing a relapse in catatonia necessitating multiple rounds of ECT.<sup>1,4</sup>
- Our case demonstrates that **short courses of ECT in HD patients can be helpful both for remission of catatonia**, as well as symptoms of depression.
- Given ECT's ability to help with depression, psychosis, and catatonia, **it should be strongly considered in HD patients who are severely debilitated and treatment-resistant**.
- Our patient has had **sustained improvement** in depression, anxiety, catatonia, and suicidality over 5 months following 15th and final treatment; we were able to minimize polypharmacy.

## References

- <sup>1</sup>Merida-Puga, J., Ramirez-Bermudez, J., Aguilar-Venegas, L. C., Fricchione, G. L., & Espinola-Nadurille, M. (2011). Westphal variant Huntington disease and refractory catatonia: a case report. *Cognitive and behavioral neurology: official journal of the Society for Behavioral and Cognitive Neurology*, 24(4), 204–208.
- <sup>2</sup>Mowafi, W., & Millard, J. (2021). Electroconvulsive therapy for severe depression, psychosis and chorea in a patient with Huntington's disease: case report and review of the literature. *BJPsych bulletin*, 45(2), 97–104.
- <sup>3</sup>Cusin, C., Franco, F. B., Fernandez-Robles, C., DuBois, C. M., & Welch, C. A. (2013). Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. *General hospital psychiatry*, 35(6), 678.e3–678.e678005.
- <sup>4</sup>Ranen, N. G., Peyser, C. E., & Folstein, S. E. (1994). ECT as a treatment for depression in Huntington's disease. *The Journal of neuropsychiatry and clinical neurosciences*, 6(2), 154–159.